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1. Introduction
Although the incidence of gastric cancer has been declining in most industrialized countries
over the past two decades, it still remains the second leading cause of cancer related deaths
worldwide [1]. The incidence is highest in Japan, Korea, China, Latin America and Eastern
Europe. In western countries like the United States, the incidence is lower, with 21,000 new
cases diagnosed each year [2]. Gastric carcinoma is one of the most frequent malignancies in
the world and its clinical behavior especially depends on the metastatic potential of the tumor.
In particular, lymphatic metastasis is one of the main predictors of tumor recurrence and
survival, and current pathological staging systems reflect the concept that lymphatic spread
is the most relevant prognostic factor in patients undergoing curative resection [3]. This is
compounded by the observation that two-thirds of gastric cancer in the Western world
presents at an advanced stage, with lymph node metastasis at diagnosis [4].
2. Patterns of relapse and metastasis
Gastric cancer can spread via direct extension, lymphatic and hematogenous routes and also
peritoneal invasion. There are 5 ways of recurrence following surgical removal of gastric
carcinoma: lymph node, remnant stomach, local, peritoneal and hematogenous recurrence.
Sixty percent to 72% of gastric cancer patients succumb to recurrences within the first 2 years.
Hematogenous or lymphatic spreads without intra abdominal metastases occur rarely. It may
be postulated that gastric cancer prefers to spread intra abdominally, and that locoregional
control is therefore an important issue in treatment strategy [5]. Locoregional recurrence rates
vary from 25% to 96% depending on different detection methods and study populations.
Several prognostic factors have been identified.
© 2013 Akturk and Ulusoy; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
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3. Stage
The pathologic stage has consistently been shown to be of prognostic significance for both
5year survival and local recurrence rates [6]. The best prognosis is seen in patients with early
stage of the cancer. The survival rates that come from the National Cancer Institute's SEER
database and which are based on people diagnosed with stomach cancer and treated with
surgery between 1991 and 2000 are as follows. (Table 1)
Table 1. Add caption
4. Histology and recurrence
Gastric cancer can recur in different pathways. The possibility of predicting the risk and type
of recurrence in patients with resectable gastric cancer could have important implications for
therapy, both in the surgical approach (extent of lymphadenectomy, partial or total resection)
and in complementary therapies. Marelli et al. found out that the main difference was found
on the onset of peritoneal recurrence in a study of 412 patients in which they compared the
recurrence patterns of intestinal type and diffuse type [7]. Shiriashi et al. confirmed that most
recurrences were within the first two years after surgery and rare after 5 years [8].
For intestinal type of the tumor lymph node positivity, depth of invasion, advanced age and
male gender significantly increases the risk of recurrence. The patterns of relapse were mainly
locoregional or hematogenous and peritoneal recurrence was limited. For diffuse type of
tumors very high rates of peritoneal recurrence were observed in neoplasms with infiltration
of the serosa, involvement of second level lymph nodes, and large tumor size. Locoregional
recurrences were frequent in advanced forms, lymph node–positive cases, and tumors larger
than 4 cm. The rate of hematogenous recurrence was generally smaller than that of peritoneal
or locoregional disease. Early forms and tumors smaller than 4 cm recurred primarily via
hematogenous route.
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The main difference was found in the onset of peritoneal recurrence; this was observed in 34%
of diffuse-type cases compared to 9% of intestinal-type cases, and was the main pathway of
spread in the former. Compared to intestinal-type cells, the diffuse type showed a greater
predisposition to proliferate in the peritoneum, considering that 50% of the cases with
infiltration of the serosa led to peritoneal carcinomatosis, which was observed in only 16% of
T3 and T4 intestinal-type cases. On the contrary, recurrences of intestinal-type tumors were
mainly locoregional or hematogenous. The incidence of hematogenous recurrence did not
show significant differences between the intestinal and the diffuse types; in both groups of
patients, they observed a higher frequency of this recurrence in lymph node– positive cases,
a finding in accord with other reports. However, the degree of involvement in the various
organs was different, because the intestinal type metastasized primarily to the liver, whereas
in the diffuse type the liver was involved in only half of the cases; in the other cases, hema‐
togenous metastases involved distant organs. The data may suggest that in the diffuse type,
but not in the intestinal type, superextended lymphadenectomy may play a more important
role in reducing the risk of recurrence. The diffuse type may show a greater propensity than
the intestinal type to metastasize to third- and fourth-level lymph nodes [7].
In a large series Nakamura et al. demonstrated that there is some correlation between the tumor
histological type and the gross type. Seventy nine percent of diffusely infiltrating tumors and
69% of ulcerative infiltrating tumors were poorly differentiated and 60% of polipoid tumors
were well differentiated in advanced carcinomas. In early carcinomas 89% of Type 1 and 77%
of Type IIa lesions were well differentiated. Type llc tumors were either well (31%), moderate
(19%) or poorly differentiated (50%). In their large series of 10 thousand patients the most
frequently encountered macroscopic type of advanced carcinoma was the ulcerative infiltrat‐
ing tumor (41%), followed by ulcerating circumscribed type (31%). In early carcinomas type
IIc (70%) was the most frequently encountered type, followed by Type II a. In advanced forms
well differentiated types showed fairer prognosis [9].
Adachi et al. demonstrated that patients with poorly differentiated type show a poorer
prognosis especially when the tumor is bigger than 10 cm or serosal involvement is positive.
If the tumor did not invade serosa but had lymph node metastasis, survival rate was signifi‐
cantly lower in the well differentiated group [10]. Moriguchi et al. also demonstrated that when
the tumor invasion was restricted within mucosa or submucosa the well differentiated type of
tumor were associated with poorer prognosis [11]. This difference can be explained by the
characteristics of well differentiated type which readily develops blood-bourne metastases
irrespective of the degree of penetration by tumor cells [10].
5. Grade
The difficulty of assessing the prognosis of gastric cancer using histological methods is well
known and this is also reflected in the essentially descriptive character of presently used
classifications [12]. In a study by Chiaravalli et al. which they reviewed the effect of the grade
on prognosis among patients with T2-T4 cancer, the more favorable behavior of grade 1
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compared to grade 2 tumors and of the latter compared to grade 3 cases was confirmed. Among
diffuse type cancers a low low-grade desmoplastic type with a significantly better prognosis
and worse prognosis of a high-grade anaplastic subtype were identified histologically from
the bulk of diffuse gastric cancers owing to their distinctive histologic, clinicopathologic, and
prognostic aspects. [13]. However, the stage itself, with special reference to lymph-node
metastases and invasion level beyond subserosa, remains the most important prognostic clue
for gastric cancer [14].
Tumor size: In a study by Yokota et al., which they reviewed 697 patients with gastric cancer,
the patients were divided into three groups: 102 patients with tumors of less than 2 cm in
diameter, 392 patients with tumors of 2-7 cm in diameter, and 203 patients with tumors of more
than 7 cm in diameter. Patients with larger tumors had more invasion into the gastric wall in
terms of depth of invasion and more frequent lymph node metastasis than did patients with
smaller tumors. Histologically, diffuse, scirrhous-type was more common in the larger tumor
group. The frequency of lymphatic and vascular permeation in the larger tumor group was
higher than that in the other groups. The 5-year survival rates according to tumor size were
94.3% in cases of tumors of less than 2 cm, 75.1% in cases of tumors of 2-7 cm, and 26.3% in
cases of tumors of more than 7 cm. Multivariate analysis revealed that the prognosis of gastric
cancer patients was affected most by depth of invasion, followed by lymph node metastasis
and tumor location. Tumor size is not an independent prognostic factor. In conclusion,
according to the results of univariate analysis, tumor size is clinically a predictor of survival
of patients with gastric cancer. In multivariate analysis, however, it is not an independent
factor, and the presence of lymph node metastasis, depth of invasion and tumor location are
more important than tumor size (15). However in another study of clinicopathologic data of
479 patients who underwent curative operation for gastric carcinoma, the patients were
divided into three groups: 182 with tumors measuring <4 cm (group I), 252 with tumors of 4–
10 cm (group II), and 45 with tumors of 10 cm (group III). The 10year survival rates for group
I, II, and III patients were 92%, 66%, and 33%, respectively (p<0.01), and the three groups were
significantly different with regard to depth of invasion (p<0.01), number and level of lymph
node metastasis (p<0.01), and stage of disease (p<0.01). Multivariate analysis indicated that
tumor size independently influenced the survival of patients. [16] Among patients with gastric
cancer larger than 10 cm, independent prognostic factors were serosal invasion, extragastric
lymph node metastasis, and liver metastasis. Prognosis after gastrectomy was determined by
these tumor factors and was not associated with the patient or operation factors [17].
6. Tumor location
Middle third and distal cancers tend to decline worldwide. However, in the western popula‐
tions proximal gastric cancers tend to increase even though the incidence of those cancers stays
the same in Japan [18]. In a study by Saito et al, tumors of the cardia had a mean size of 6.8 cm,
which was significantly larger than the mean size of 5.9 cm for tumors found in the middle-
and lower third of the stomach. The incidence of serosal invasion, lymph node metastasis, and
lymphatic and blood vessel invasion was higher in association with adenocarcinoma of the
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cardia than with adenocarcinoma in remaining parts of the stomach. In the analysis of patients
who had undergone curative resection, the 5-year survival rates were 61.6%, 79.1%, and 82.6%
in patients with carcinoma of the cardia, upper one-third, and remaining middle- and lower
one-third of the stomach, respectively, and the differences were statistically significant.
Multivariate analysis indicated that adenocarcinoma of the gastric cardia is an independent
prognostic factor. With regard to the site of recurrence, both lymph node and hematogenous
recurrence were observed more frequently in the cardia than in the remaining parts of the
stomach [19]. A multivariate analysis demonstrates that R0 resection is independent of other
strong predictors of survival, like T, N and M [20].
7. Lymphatic and vascular invasion
Hyung et al. reviewed a total of 280 patients who underwent curative gastrectomy for
advanced gastric cancer without lymph node metastasis. Lymphatic vessel invasion (LVI) was
noted in 20.0%, blood vessel invasion (BVI) in 5.4%, and either LVI or BVI in 22.5%. None of
the clinicopathologic features was related to LBVI. Patients with LBVI had a recurrence rate
of 26.8%, whereas patients without LBVI had a recurrence rate of 13.5%. The 5-year survival
rates were 82.4% for patients without LBVI and 67.1% for patients with LBVI. LBVI was shown
to be an independent risk factor for recurrence [21]. Del Casar et al. reviewed 144 patients with
primary gastric adenocarcinoma, who consecutively underwent surgery with a mean follow
up of 33 months. LBVI was present in 46 patients (31.9%). The presence of LBVI correlated
significantly with tumor stage, lymph node involvement, surgical resectability, histological
type and histological grade, being present in a higher percentage among II-IV tumor stage,
poorly differentiated, diffuse type, R1-R2 and lymph node-positive tumors. In addition,
statistical analysis demonstrated that LBVI was significantly associated with a poorer overall
patients' survival in the univariate analysis as well as in the multivariate analysis. However,
their results failed to show any significant relationship between LBVI and any of the intratu‐
moral biological parameters studies [22].
LBVI is an adverse prognostic indicator and the presence of LBVI seems to provide useful
information for the prognosis and clinical management of patients with node-negative
advanced and also early gastric carcinoma [23].
8. Peritoneal cytology
Mezhir et al. demonstrated that a positive peritoneal cytology, even in the absence of gross
peritoneal disease, indicates a poor outcome [24, 25]. In the Dutch Gastric Cancer Group,
positive cytological findings were found in 4.4% of the patients and were indicative of a poor
prognosis, with a median survival of 13 months [26]. Thus, the Japanese Society for Gastric
Cancer has included peritoneal cytology as part of the staging procedure, while the TNM
classification system has classified cytology-positive gastric cancer patients as stage IV patients
since 1997 [27,28].
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9. Lymph node ratio
Xiao et al. reviewed the significance of metastatic lymph node ratio in gastric cancer and
compared it to N staging of 7th edition of UICC [29]. Lymph node metastasis is one of the most
important gastric cancer prognostic factors [30]. The identified number of involved lymph
nodes depends on the number of lymph nodes removed and examined, which in turn depends
on the surgical and pathologic procedures. Although TNM classification is a convenient and
reproducible method for precise staging, it demands the examination of at least 15 lymph
nodes. If the number of dissected and examined lymph nodes is small, down-migration of N
stage may occur, and conversely, if the number is large, upmigration of N stage may occur,
which is also referred to as stage migration in some references [31,32]. To improve prognosis
prediction, the number of positive lymph nodes should be considered in the context of the
number of nodes examined. The metastatic lymph node ratio (MLNR), defined as the number
of positive lymph nodes divided by the number of lymph nodes retrieved, has been proposed
as an alternative to classification systems that assess the absolute number of positive lymph
nodes [29]. In a study by Nitti et al. the 5-year survivals according to the metastatic/examined
lymph nodes ratio (N ratio) were 14%, 50%, 61%, and 82% in the group of patients with N ratio
>25%, 11%-25%, 1%-10%, and 0%, respectively (P <.0001). At multivariate analysis, the N ratio
was the best single independent prognostic factor [33]. In a study by Kulig et al., it was said
that even though the LNR cannot be used as a substitute for staging with adequate lympha‐
denectomy, it may help to stratify patients in terms of prognosis when the number of resected
lymph nodes is limited and therefore the stage is inadequately defined [34]. The metastatic
lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenec‐
tomy for gastric adenocarcinoma [35]. Xu et al. stated that positive N ratio classification is a
better prognostic tool compared with N staging system after D2 resection in patients with
gastric cancer. It can prevent stage migration and can be used regardless of the examined
number of lymph nodes [36].
10. Age
In a review by Wang et al., it is stated that the prognostic value of age in gastric cancer patients
remains controversial [37]. Some researchers thought that it was not an independent prog‐
nostic factor [38-40], whereas others thought that younger patients has worse prognoses than
elderly due to the worse biological behaviors of tumors and histological type [41]. However,
Saito et al. held that elderly patients had worse prognosis because they had limited lymph
node dissection and lower tolerance of chemotherapy [42].
11. Genomics and prognosis
Gastric cancer is said to be a chronic proliferative disease with multiple genetic and epigenetic
alterations [43-44]. The specific combination of alterations differs in the 2 histological types of
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gastric cancer, suggesting that intestinal-type and diffuse-type carcinomas have distinct
carcinogenetic pathways. Chromosomal instability (CIN); in particular, loss of heterozygosity
(LOH), genomic amplifications, and DNA aneuploidy, are frequently observed in intestinal-
type gastric carcinoma [45, 46]. Intestinal type of gastric cancer is thought to be generated after
a multistep process of intestinal metaplasia-dysplasia-carcinoma [47]. This process of intestinal
type gastric cancer development mimics the progression from adenoma to colon carcinoma,
which results from the accumulation of molecular genetic alterations involving activation of
oncogenes and inactivation of tumor suppressor genes [48]. Microsatellite instability and p53
mutation, reduced p27 expression, cyclin E overexpression and 6.0kb transcripts of the c-met
gene are involved in malignant transformation from precancerous lesions to intestinal-type
gastric cancer. In addition, DCC loss, APC mutations, 1q loss of heterozygosity (LOH), p27
loss, reduced expression of tumor growth factor (TGF)β type I receptor and HER2 gene
amplification are frequently associated with an advanced stage of intestinal-type gastric
carcinoma [49]. Diffuse type gastric cancer is considered to be de novo cancer, and precursor
cells have not yet been identified [47]. In contrast, LOH at chromosome 17p (p53) and mutation
or loss of E-cadherin are more often implicated in the development of diffuse-type gastric
cancer, while loss of p27 and gene amplification of Ksam and c-met lead to disease progression
and metastatic spread [49].
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